Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
TERAZOL 7 is a vaginal antifungal cream approved in 1987 for the treatment of vaginal yeast infections (vulvovaginal candidiasis). The active ingredient is terconazole, an azole-class antifungal that disrupts fungal cell membrane integrity. This over-the-counter product represents a mature, well-established therapeutic option in the gynecological antifungal category.
As a mature, legacy product approaching loss of exclusivity with low competitive pressure (30%), the brand team is likely operating on efficiency and retention strategies with smaller dedicated headcount.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on TERAZOL 7 offers limited career acceleration opportunity given its mature, commoditized status and approaching LOE. Roles on this product are primarily focused on margin protection, customer relationship management, and defending market share against generics rather than innovation or strategic growth.
Worked on TERAZOL 7 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.